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 This dissertation is the first to empirically test an asset measurement framework 
that links asset measurement to asset use. Specifically, I examine whether fair value 
applied to in-exchange assets and historical cost applied to in-use assets (i.e. 
measurement consistent with asset use) produces incrementally more value relevant 
information than when historical cost is applied to in-exchange assets and fair value is 
applied to in-use assets (i.e. measurement inconsistent with asset use). I test the 
framework on a sample of 182 international firms from 33 different countries that adopt 
International Accounting Standard (IAS) 41. IAS 41 prescribes fair value measurement 
for biological assets, a class of assets previously classified as property, plant, and 
equipment and measured at historical cost. I find that book value and earnings 
information is more value relevant when measurement is consistent with asset use as 
compared to when asset measurement is not linked to asset use. At present, the 
Conceptual Framework provides little guidance on asset measurement and when certain 
measurement bases should be used, resulting in inconsistencies across measurement 
standards. My findings provide evidence supporting a framework for asset measurement, 
which links asset measurement to asset use. These findings should be of interest to 
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Assets generate value via two mechanisms. In-exchange assets (e.g. cash) 
generate value on a standalone basis in exchange for cash or other valuable assets, while 
in-use assets (e.g. property, plant, and equipment (hereafter, PP&E)) generate value in 
combination with other assets. Early accounting theorists link value relevant asset 
measurement to the manner in which an asset generates value (e.g. Littleton 1935). 
Specifically, this literature claims that fair value applied to in-exchange assets and 
historical cost applied to in-use assets has the potential to produce incrementally more 
value relevant information for investors. Nevertheless, in some cases, modern accounting 
standards do not link asset measurement to the manner in which the asset generates value. 
For example, International Accounting Standard (hereafter, IAS) 41 requires fair value 
measurement for “biological assets,” which are living plants and animals, regardless of 
whether the biological assets derive value in-use or in-exchange.  
I use the adoption of IAS 41 as a setting to examine whether asset measurement 
linked to asset use provides investors with incrementally more value relevant 
information. The adoption of IAS 41 offers an advantageous setting to examine the 




accounting information, for several reasons.  
First, the extent to which assets derive value in-use or in-exchange varies across 
firms for similar types of biological assets. For example, some firms own cattle for meat 
production (an in-exchange asset) while other firms own cattle for dairy production (an 
in-use asset). Second, the standard provides variation in asset measurement. Prior to IAS 
41, firms measured their biological assets at historical cost and classified them as PP&E. 
Upon adoption of the standard, some firms began measuring their biological assets at fair 
value while others applied the historical cost stipulation, discussed further in Chapter 3. 
Therefore, IAS 41 provides a setting where some firms measure their biological assets in 
a manner consistent with their use (i.e. historical cost for in-use assets or fair value for in-
exchange assets) while others do not (i.e. historical cost for in-exchange assets or fair 
value for in-use assets). In addition, before adoption of the standard, some firms measure 
their biological assets consistent with their use (i.e. historical cost for in-use assets) and 
then upon adoption of the standard, they do not (i.e. fair value for in-use assets). These 
combinations allow for a cross-sectional and a pre- and postadoption comparison of 
biological asset-groups where the asset measurement is consistent with the assets’ use, 
versus when it is not for both fair value and historical cost accounting.  
Third, for the firms that report their biological assets at fair value, IAS 41 is a 
“true” fair value standard: the fair value of biological assets is reported on the firm’s 
balance sheet, and any change in the fair value of the biological assets over the reporting 
period is recognized in periodic income as an unrealized gain or loss. This mitigates 
issues related to investors’ perceptions of recognized versus disclosed amounts when 




Ahmed et al. 2006), at discretion (e.g. Easton et al. 1993; Barth and Clinch 1998; Aboody 
et al. 1999), or when provided a choice (Cairns et al. 2011; Christensen and Nikolaev 
2013). 
I employ a sample of 182 international firms from 33 countries that adopt IAS 41. 
In a multipronged approach, I assess the value relevance of book value and earnings 
information in regressions of stock price, stock returns, future operating cash flows, and 
future operating income. I separate my sample into two subsamples. The first “consistent 
measurement” subsample includes observations for which the measurement of biological 
assets is consistent with their use (i.e. where in-exchange biological assets are measured 
at fair value and in-use biological assets are measured at historical cost). The second 
“inconsistent measurement” subsample includes observations for which the measurement 
of biological assets is inconsistent with their use (i.e. where in-exchange biological assets 
are measured at historical cost and in-use assets are measured at fair value).  
My results are as follows. First, in the cross-sectional tests, I find strong support 
for my hypothesis, that when measurement is linked to asset use, investors are provided 
with more value relevant information. As suggested by early accounting theorists, I find 
that book value and earnings information is more value relevant when asset measurement 
is consistent with the manner in which the asset realizes value for the firm, relative to 
when it is not. Specifically, I find that book value and earnings information is more value 
relevant when in-exchange (in-use) assets are measured at fair value (historical cost) as 
compared to when in-exchange (in-use) assets are measured at historical cost (fair value).  
I supplement my cross-sectional findings by comparing the value relevance of 




historical cost to fair value upon adoption of IAS 41, the “switcher” sample. The results 
provide mixed evidence. Specifically, I find strong evidence that book value per share 
became significantly more (less) value relevant for firms that held in-exchange (in-use) 
biological assets and began measuring them at fair value upon adoption of the standard. 
However, I find no other statistically significant results in the return tests or the 
mechanical forecasting models of future operating cash flows and operating income. In 
future work, I plan to hand-collect the interim fiscal year IAS 41 disclosures in order to 
increase my sample, and consequently, the power of the switcher test.  
Overall, my findings provide some empirical support for early accounting theory 
that links value relevant asset measurement to the way in which the asset generates value 
(e.g. Littleton 1935; May 1936). Further, my findings support the International 
Accounting Standards Board’s (hereafter, IASB) recent proposed revisions to the 
measurement section of its Conceptual Framework. Specifically, the IASB (2013a, ¶6.16) 
proposes that the relevance and selection of a particular measurement basis depends on 
how the asset contributes to the entity’s future cash flows, i.e. is used by the firm, and 
this occurs either directly (i.e. in-exchange) or in combination with other assets (i.e. in-
use). 
This paper makes several contributions to the literature. First, to my knowledge, it 
is the first to test and provide empirical support for an asset measurement framework that 
links asset measurement to asset use. This should be of interest to accounting standard 
setters since the Financial Accounting Standards Board (hereafter, FASB) and the IASB 




measurement standards.1 As a result, asset measurement guidance continues to be a hotly 
contested standard setting issue and inconsistencies exist across standards. 2  Thus, a 
framework to guide standard setters’ asset measurement choices and to support high-
quality, consistent standard setting is greatly needed. I believe my findings provide 
evidence supporting a systematic framework for asset measurement that could inform 
standard setters’ decision-making processes on future asset measurement standards.  
Second, my findings provide evidence that the asset measurement investors find 
useful in assessing firm value is sometimes, but not always, fair value, and similarly for 
historical cost. This is in contrast to the current academic debate over asset measurement, 
which tends to side with either fair value or historical cost. Instead, my findings support 
the IASB’s (2013a, ¶6.14) view on measurement bases which states, “… the IASB’s 
preliminary view is the Conceptual Framework should not recommend measuring all 
assets and liabilities on the same basis.” By understanding which asset measurement 
investors find useful in determining firm value, the accounting community is better 
positioned to understand cost-benefit tradeoffs and how to improve the effectiveness of 
financial statement disclosures, a primary objective of the FASB’s disclosure framework 
project (FASB 2012).  
Finally, much of the prior literature examining fair value measurement 
investigates whether fair value is sufficiently reliable to be value relevant to investors, 
                                                 
1
 For example, the opening paragraph of the measurement section from the IASB’s (2013a, ¶6.1) discussion 
paper of its conceptual framework states: “The existing Conceptual Framework provides little guidance on 
measurement and when particular measurement should be used.”  
2
 The objective of the IASB and FASB’s joint project on an improved conceptual framework for financial 
reporting is “…for their standards to be clearly based on consistent principles. To be consistent, principles 
must be rooted in fundamental concepts rather than a collection of conventions” (as quoted in Milburn 




beyond measurement at historical cost.3 This relative reliability perspective differs from a 
business valuation perspective, which links value relevant asset measurement to the 
manner in which the asset realizes value, not to the relative reliability of the measure. In 
contrast to the relative reliability research, I find that fair value information is more value 
relevant for in-exchange biological assets than in-use biological assets, even after 
controlling for cross-sectional differences in measurement reliability. That is, in my 
study, value relevance is a function of asset use, not the reliability of the fair value 
measure. 4  I seek to supplement and contribute to the extant literature by providing 
evidence regarding the link between value relevant asset measurement and the manner in 
which assets realize value. 
                                                 
3
 See, for example, among others: Easton et al. 1993; Barth 1994a,b; Bernard et al. 1995; Barth et al. 1996; 
Barth and Clinch 1998; Aboody et al. 1999; Song et al. 2010. 
4
 The fair value of both in-exchange and in-use biological assets is often measured using a discounted cash 
flow approach, considered a “Level 3” estimation as defined by Statement of Financial Accounting 
Standard (SFAS) 157 (FASB 2006). Research suggests that investors perceive Level 3 estimates as less 
reliable than “Level 1” or “Level 2” estimates of fair value, which employ market prices (e.g. Kolev 2009; 











2.1 Asset Measurement Frameworks 
 Prior research identifies standard setters’ lack of a systematic framework to guide 
asset measurement standards as a weakness of the Conceptual Framework (see Agarwal 
1987; Barth 2007; Barth 2014). The IASB explicitly acknowledges its lack of a 
framework to guide asset measurement standards in the opening paragraph of the 
measurement section of the IASB’s (2013a, ¶6.13) recent proposed revisions to its 
Conceptual Framework, which states: “The existing Conceptual Framework provides 
little guidance on measurement and when a particular measurement basis should be 
used.” As a result, inconsistencies exist across asset measurement standards. For 
example, under United States Generally Accepted Accounting Principles (hereafter, U.S. 
GAAP) investment property is recognized at cost, while under IFRS, investment property 
can be recognized at fair value (KPMG 2012). Similarly, under IFRS, PP&E can be 
recognized at cost, but biological assets, which were formerly classified as PP&E and 
measured at cost, are required to be recognized at fair value (KPMG 2012). As Cooper 
(2007, 17) states, the lack of a measurement framework has resulted in, “… a large 




underlying logic.”5 Further, Barth (2014) argues that the Conceptual Framework’s lack of 
measurement concepts is a major impediment to improving financial reporting. 
A potential framework to guide asset measurement appears in early accounting 
literature. Specifically, early accounting theorists link asset measurement to asset use (see 
Littleton 1935; May 1936). In this literature, assets derive value either in-exchange or in-
use. Assets that derive value in-exchange do so on a standalone basis, independent of 
other firm assets. The value of such assets to the firm is market driven with no 
incremental value created by using the asset in combination with other assets. Examples 
of in-exchange assets include financial securities or a tractor being held for sale. On the 
other hand, assets that derive value in-use do so in combination with other firm assets 
such that they create value incremental to the sum of the individual assets’ exchange 
values. Examples of in-use assets include PP&E that is used for productive purposes. 
Specifically, this literature argues that fair value applied to in-exchange assets and 
historical cost applied to in-use assets has the potential to provide investors with 
incrementally more value relevant information to forecast firm value (e.g. Littleton 
1935).  
Indeed, some modern-day accounting standards require different measurement 
bases depending upon the firm’s use of the asset. For example, Statement of Financial 
Accounting Standard (SFAS) 144 requires firms to recognize PP&E at the lower of its 
carrying amount or fair value less costs to sell if the assets are being held for sale (FASB 
2010). Otherwise, PP&E is recognized at cost on the balance sheet. Although some 
                                                 
5
 In a similar sentiment, Barth (2014, 1) writes that as a result of the Conceptual Framework’s lack of a 
measurement framework, “…standard setting measurement decisions have been necessarily ad hoc and 
based more on historical precedent and the combined judgment of individual FASB and IASB members 




financial accounting standards link measurement to asset use, consistent with early 
accounting theory, this approach has not been adopted at the Conceptual Framework 
level. Further, there has been no empirical evidence on whether linking measurement to 
asset use provides investors with more value relevant information. This paper provides an 
empirical test of the theory. 
In contrast to early accounting theory, advocates of fair value accounting propose 
fair value as the value relevant measurement basis for both in-exchange and in-use assets, 
as long as the fair value can be reliably estimated. Specifically, this research argues that if 
fair value can be captured using quoted market prices, a Level 1 estimate from the fair 
value measurement hierarchy defined by SFAS 157 (FASB 2006), it will provide 
investors with value relevant information (e.g. Barth and Landsman 1995; Dietrich et al. 
2000; Barth et al. 2001; Landsman 2007). Generally, fair value advocates argue that fair 
value information is more relevant to investors than historical cost information for both 
in-exchange and in-use assets (e.g. Barth et al. 2001; Landsman 2007). 
 
2.2 Research on Fair Value Accounting 
 Consistent with both early accounting theory and fair value advocates, prior 
empirical research has repeatedly established the value relevance of fair value 
measurement for a specific class of in-exchange assets: financial securities.6 Moreover, 
these findings extend to investors’ use of fair value measurement information for 
financial securities under all three levels of the fair value measurement hierarchy defined 
by SFAS 157: quoted prices for identical assets (Level 1), quoted prices of similar assets 
                                                 
6
 These studies consistently find that investors perceive fair value estimates for financial securities as more 
value relevant than historical cost amounts: Barth 1994a, b; Ahmed and Takeda 1995; Bernard et al. 1995; 




(Level 2), and fair value measured using valuation techniques (Level 3) (Kolev 2009; 
Song et al. 2010). Consistent with these findings, recent research finds no difference in 
the value relevance of Level 1 versus Level 3 inputs for financial securities (Lawrence et 
al. 2014), and that Level 3 inputs best capture the underlying cash flows generated from 
financial securities when markets are inactive (Altamuro and Zhang 2013). Accordingly, 
the value relevance of fair value information is not simply a function of measurement 
reliability.  
The empirical research on the relevance of fair value for financial securities 
provides the strongest evidence in favor of fair value as the value relevant measurement 
basis. Financial securities, however, derive value in-exchange, not in-use. Therefore, the 
fair value research on financial securities does not distinguish between the two asset 
measurement frameworks, early accounting theory versus fair value advocates: there is 
little variation in the manner in which financial securities are expected to realize value for 
the firm. Moreover, whether fair value provides investors with value relevant information 
for in-exchange assets that are not financial securities is an empirical question that I test 
in this paper. 
Empirical research regarding equity investors’ use of fair value measurement for 
nonfinancial assets provides mixed findings. First, the studies do not clarify whether the 
nonfinancial assets derive value in-use or in-exchange. Second, the research examining 
the value relevance of fair value for nonfinancial assets is burdened by the lack of 
mandated measurement variation across in-use asset classes. Accordingly, early research 
examining investors’ use of fair value information for in-use assets examines disclosed 




research fails to find that current cost disclosures are value relevant (e.g. Beaver and 
Landsman 1983; Beaver and Ryan 1985; Bernard and Ruland 1987; Hopwood and 
Schaefer 1989; Lobo and Song 1989). The lack of relevance, however, could be 
attributed to investors’ perceptions of disclosed values as less reliable or relevant than 
recognized amounts (see Ahmed et al. 2006). 
Later empirical research examining investors’ use of fair value measurement for 
nonfinancial assets employs settings in which United Kingdom (hereafter, U.K.) and 
Australian firms made discretionary revaluations to their tangible long-lived assets. 
Generally, this research provides evidence that investors find the asset revaluations value 
relevant in stock price and return estimations (e.g. Easton et al. 1993; Barth and Clinch 
1998) and in mechanical forecasting models of future operating cash flows and operating 
income (Aboody et al. 1999). However, a problem drawing inferences from the 
discretionary asset revaluation research is that managers decide to revalue ex-post and 
therefore may revalue for a host of reasons that are unrelated to providing investors with 
value relevant information, i.e. when they need to manage reported performance 
(Christensen and Nikolaev 2013).  Again, the studies do not clarify whether the 
nonfinancial assets in question derive value in-use or in-exchange. 
More recent empirical research on fair value measurement of nonfinancial assets 
examines firms’ measurement choice for nonfinancial assets upon adoption of IFRS. 
Both Cairns et al. (2011) and Christensen and Nikolaev (2013) find that few U.K., 
Australian, and German firms choose to measure their nonfinancial assets at fair value 
upon adoption of IFRS. Instead, Christensen and Nikolaev (2013) find that firms almost 




(i.e. in-use assets).  
Some research attributes the mixed evidence on the relevance of fair value 
measurement for nonfinancial assets to the lack of reliability of the fair value estimates 
(e.g. Barth et al. 2001). Instead, I argue that prior research has not carefully considered 
the role asset use might play in determining which asset measurement basis is value 
relevant. Thus, the mixed results could be linked to the confounding factor of asset use as 
opposed to variation in the reliability of the estimates. I empirically test whether fair 
value or historical cost measurement for in-use assets provides investors with more value 
relevant information on a sample of firms that adopt IAS 41.   
 
2.3 Research on Historical Cost Accounting 
 Unlike the research on fair value accounting for nonfinancial assets, there is little 
empirical research on the value relevance of historical cost for in-use assets. Most of the 
literature arguing that historical cost may provide investors with value relevant 
information for in-use assets relies on business valuation theory, including Littleton 
(1935) and May (1936). Specifically, this literature focuses on the information investors 
require to forecast the cash flows in-use assets generate. For example, Deans (2007, 31) 
argues, “…it is harder to see how knowing the fair values (exit values) of [in-use] assets 
that generate cash flows helps in forecasting those cash flows.” Cooper (2007, 17) argues 
that while historical cost may not be relevant when making an economic decision with 
respect to a specific asset, for example deciding whether to sell an asset, not all decisions 
are made on an asset-by-asset basis. Instead, Cooper (2007) argues that for in-use assets, 




immediate sale is not intended, historical cost best captures the overall profitability of the 
business venture.  
In addition, Nissim and Penman (2008) maintain that historical cost accounting is 
designed for business models where the firm transforms inputs to add value, i.e. in-use 
assets. Similarly, a measurement framework developed by the Institute of Chartered 
Accountants in England and Wales (2010) advocates for historical cost accounting as the 
most relevant measurement basis when the firm’s business model is to transform inputs 
so as to create new assets or services as outputs, i.e. in-use assets. Additionally, Botosan 
and Huffman (2014) argue that historical cost provides investors with relevant 
information for in-use assets because historical cost information is useful to investors in 
forecasting the future cash flows from in-use assets. Finally, the IASB (2013a, ¶6.16b) 
states that for assets deriving value in-use, investors may find historical cost more 
relevant than fair value because historical cost preserves the margins generated by past 
transaction that investors find useful in estimating future margins to forecast the cash 
flows in-use assets generate. The IASB (2013a, ¶6.16b) states, “Changes in the market 
price of [in-use assets]… may not be particularly relevant for this purpose.”  
Whether asset measurement linked to asset use provides investors with value 
relevant information is an empirical question I test in this paper. In particular, whether 
fair value measurement provides investors with value relevant information for in-
exchange assets that are not financial securities, and whether fair value or historical cost 
measurement provides investors with value relevant information for in-use assets remain 




that measurement linked to asset use provides investors with value relevant information 










MOTIVATION AND HYPOTHESES 
 
3.1 IAS 41 Background 
 The International Accounting Standards Committee, the IASB’s predecessor, 
issued IAS 41 in 2001 in order to develop more uniform accounting practices for 
agricultural activities (IASB 2006). The standard became effective for annual reporting 
periods beginning on or after January 1, 2003, or alternatively, upon adoption of IFRS. 
IAS 41 prescribes accounting treatment for biological assets, which are living plants and 
animals. 7  Biological assets are held by firms involved in agricultural activity. 
Agricultural activities that produce or employ biological assets include raising livestock, 
forestry, cropping, cultivating orchards and plantations, floriculture, and aquaculture 
(IASB 2009, ¶6). 
 Prior to the passage of IAS 41, agricultural activity was excluded from the scope 
of international accounting standards (IASB 2012, ¶8). Accounting guidelines for 
agricultural activities were developed by national standard setters on a piecemeal basis to 
resolve specific issues (IASB 2012, ¶8b). Pre-IAS 41, most firms accounted for their 
biological assets at historical cost and classified the assets as PP&E on the balance sheet. 
                                                 
7
 Specifically, IAS 41 prescribes accounting treatment for agricultural activity, or “management by the 
entity of the biological transformation of living animals and plants (biological assets) for sale, into 





Consequently, the assets were subject to impairment analysis. Upon adoption of the 
standard, however, firms line item the value of their biological assets on the balance 
sheet, separate from PP&E.  
The passage of IAS 41 offers a unique setting to test whether asset measurement 
linked to asset use provides investors with value relevant information, for several reasons. 
First, variation exists in the manner in which firms employ their biological assets to 
realize value. Specifically, IAS 41 encourages firms to distinguish between “consumable” 
and “bearer” biological assets in order to provide information that may help investors to 
assess the timing of future cash flows (IASB 2009, ¶43). This distinction maps closely 
into the way in which the biological assets are expected to realize value for the firm. 
Consumable biological assets are agricultural products, like crops or timber, or sold as 
biological assets, like commodities (IASB 2009, ¶44). Consumable biological assets 
realize value on a standalone basis and their value to the firm is linked to what the asset 
might be exchanged for in the marketplace. Thus, these assets are closer in nature to in-
exchange assets. Bearer biological assets, on the other hand, are self-regenerating assets, 
like orchards or oil palm plantations (IASB 2009, ¶44), which are employed in 
combination with other assets in the on-going operations of the firm. Thus, bearer 
biological assets realize value in combination with other assets and are therefore closer in 
nature to in-use assets. I employ IAS 41’s definition of consumable and bearer biological 
assets to proxy for the assets’ value realization, either in-exchange or in-use, respectively. 
Second, IAS 41 provides a setting with mandated measurement variation. Prior to 
adoption of IAS 41, firms measured their biological assets at historical cost and classified 





although the standard allows firms to measure their biological assets at historical cost if 
the firm is able to demonstrate that the fair value of its biological assets cannot be reliably 
estimated, i.e. there is a lack of reliable parameters such as known prices, growth rates, or 
physical volumes of the asset (IASB 2009, ¶30). I utilize this measurement variation in 
my research design. Specifically, 41% (789 observations) of the firm-year observations in 
my sample contain biological assets measured at cost, while 41% of the firm-year 
observations contain biological assets measured at fair value (see Figure 3.1). Of the cost 
sample, 237 observations are post-IAS 41 firm-year observations where firms applied the 
historical cost stipulation. The measurement variation in the sample of firms that apply 
the historical cost stipulation postadoption of IAS 41 appears to be driven at the country 
level. Specifically, it appears that certain countries are enforcing IAS 41 as mandated, 
like the United Kingdom, while other countries are allowing firms to apply the historical 
cost stipulation within the standard. I include country fixed-effects in my estimations to 
control for this variation, and I also explore the effects of audit enforcement of 
accounting standards in robustness tests.  
Finally, IAS 41 is a “true” fair value standard. That is, the firms that measure their 
biological assets at fair value must recognize the value on their balance sheets and any 
change in the value of the assets over the reporting period, unrealized gains or losses, in 
income. Therefore, IAS 41 provides variation in asset measurement while helping to 
mitigate issues related to investors’ perceptions of recognized versus disclosed amounts 
when firms fair value in-use assets in disclosures (e.g. Beaver and Landsman 1983; 
Ahmed et al. 2006), or when provided a choice (Cairns et al. 2011; Christensen and 





Under IAS 41, a firm producing palm oil from oil palm trees measures its oil palm 
plantations, an in-use asset, at fair value on the balance sheet, excluding any fair value 
attributable to the land upon which the oil palms are physically attached or intangible 
assets related to the oil palm production (IASB 2009, ¶2). Thus, firms are required to 
measure and report only the oil palm trees component of the in-use assets, not the land or 
intangible assets related to the production of the palm oil, at fair value. Likewise, a firm 
that harvests logs from timber plantations, an in-exchange asset, also measures the timber 
plantations at fair value every reporting period on the balance sheet, less any costs to sell. 
Changes in the fair value of the oil palm plantations or timber (i.e. unrealized holding 
gains and losses) are recognized in periodic income (IASB 2009).  
Unlike IFRS, the term “biological assets” does not exist in U.S. GAAP or in its 
accounting for agricultural producers (KPMG 2012). Instead, the terms “growing crops” 
and “animals being developed for sale” are used to describe what would be called 
biological assets under IFRS (KPMG 2012). Under U.S. GAAP, growing crops and 
animals being developed for sale can be stated at the lower of cost or market, or at sales 
price less costs to sell if the following criteria are met: the product has a determinable 
market price, insignificant costs of disposal, and is available for immediate delivery 
(KPMG 2012). It is interesting to note that assets with these characteristics are closer in 
nature to in-exchange assets and when a sufficiently reliable measure of fair value exists, 
U.S. GAAP allows such assets to be reported at fair value determined based on exit value 
less cost to sell. 
Recently, the Asian-Oceanian Standard Setters Group (AOSSG) proposed 





the differences in the way the asset-types are used by the firm (IASB 2012). Specifically, 
the AOSSG Issues Paper (IASB 2012) argues that bearer biological assets are held for 
income generation (derive value in-use) and therefore should be treated as PP&E, which 
allows for measurement at cost, while consumable biological assets are held for sale 
(derive value in-exchange), and as such should continue to be measured at fair value. 
Moreover, the paper surveys a group of analysts specializing in plantation valuations, a 
type of bearer biological asset. The paper reports that the analysts did not find the 
reporting of the fair value of bearer biological assets as useful because the fair value, 
“…distorts the financial statements’ ability to reflect a ‘true & fair’ view of an agriculture 
company’s earnings” (IASB 2012, ¶32a). Further, the analysts said that, “… they always 
remove the biological gains or losses [from bearer biological assets] when looking at 
earnings and that end-users also do not look at fair value” (IASB 2012, ¶33). 
In response to the AOSSG Issues Paper (IASB 2012), the IASB recently issued an 
Exposure Draft (IASB 2013b) proposing to amend IAS 41 with respect to a specific class 
of bearer biological assets: bearer plants.8 Consistent with the framework I test in this 
paper, the Exposure Draft (IASB 2013b, ¶BC2) asserts that bearer plants are similar to 
PP&E, and as such, should be accounted for under IAS 16, the standard that prescribes 
measurement for PP&E, and allows for measurement at historical cost. The Exposure 
Draft (IASB 2013b, ¶BC5) argues that investors, analysts, and other users of financial 
statements did not find the fair values of bearer plants useful and would adjust reported 
statements to eliminate the effects of the fair value accounting. Further, the Exposure 
Draft (IASB 2013b) does not propose disclosing fair value amounts for bearer plants. 
Nevertheless, under IAS 41, firms measure both in-exchange and in-use 
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biological assets at fair value, and at historical cost. This allows for cross-sectional tests 
of comparison of firm-year observations where measurement is consistent with asset use 
(the consistent measurement sample), i.e. where in-exchange biological assets are 
measured at fair value and in-use biological assets are measured at historical cost, and 
firm-year observations where measurement is inconsistent with asset use (the inconsistent 
measurement sample), i.e. where in-exchange biological assets are measured at historical 
cost and in-use biological assets are measured at fair value.  
 
3.2 Main Hypothesis 
 I examine whether asset measurement linked to asset use provides investors with 
relatively more value relevant information to assess firm value than asset measurement 
that is not linked to asset use. In their joint Conceptual Framework for financial reporting, 
the FASB and the IASB characterize financial information as decision-useful if it is 
relevant and faithfully represents what it purports to represent (IASB 2010, ¶QC4). 
Relevant information, as characterized by the Conceptual Framework, is financial 
information that is capable of making a difference in the decisions made by users, i.e. it 
has predictive or confirmatory value, or both (IASB 2010, ¶QC6-¶QC7). I adopt this 
characterization of value relevant financial reporting information in my empirical tests, 
and I focus on the value relevance of financial reporting information to investors.9  
Consequently, my main hypothesis examines the relative value relevance of 
                                                 
9
 I recognize that the information needs of some users of financial reporting information are driven by 
economic decisions that are not informed by an assessment of firm value. I focus on the information needs 
of users interested in assessing firm value because a rigorous consideration of the information needs of all 
users is impractical. Moreover, I believe the users I focus on comprise an important set. This is supported 
by Dichev et al. (2012), who find that 94.7% of the public company CFOs they surveyed identify valuation 






firm’s financial statement information when biological assets are measured consistent 
with their use, relative to when they are not:  
H1: Asset measurement consistent with biological assets’ use provides investors 
with more value relevant information than measurement that is inconsistent with 












FV HC TOTAL 
Value 
Realization 
IN-USE 343 607 950 
25% 45% 70% 
IN-EXCH 216 182 398 
16% 14% 30% 
 
TOTAL 559 789 1,348 
 
 
41% 59% 100% 
 
Figure 3.1 
Value Realization and Measurement Sample Composition for the  













 I adopt a multipronged approach to test my hypothesis. I first employ cross-
sectional tests, where I examine value relevance regressions of stock price and returns, 
and mechanical forecasting models of operating cash flows and operating income for the 
sample of firms that measure their biological assets consistent with their use compared to 
the sample of firms that measure their biological assets inconsistent with the assets’ use. I 
estimate the cross-sectional tests on firm-year observations pre-IAS 41, where firms 
measured their biological assets at historical cost and classified them as PP&E, and on 
firm-year observations post-IAS 41 adoption.  
I include pre-IAS 41 observations in my cross-sectional tests for two reasons. 
First, pre-IAS 41, measurement at historical cost was not a choice: all firms measured 
their biological assets at historical cost, as part of PP&E. This avoids the potential 
selection bias of including only post-IAS 41 historical cost observations, where firms 
apply the historical cost stipulation to measure their biological assets at historical cost 
instead of fair value. Second, including the pre-IAS 41 data allows for a larger sample of 
historical cost observations: 789 observations (see Figure 3.1) versus 237 observations if 





therefore, the potential inference to be made regarding value relevant asset measurement 
and asset use.  
Next, I examine the value relevance of book value and earnings information for 
the “switcher” sample, the sample of firms that pre-IAS 41 measured their biological 
assets at historical cost and then switched measurement to fair value upon adoption of the 
standard. Figure 4.1 illustrates the approach. As described earlier, prior to IAS 41, firms 
measured their biological assets at historical cost and classified them as PP&E. 
Therefore, the adoption of IAS 41 provides a setting where firms that held in-exchange 
biological assets measured them inconsistent with their use pre-adoption, but then 
switched measurement to fair value consistent with the biological asset’s use. Similarly, 
in the pre-adoption period, some firms measured their in-use assets consistent with their 
use (at historical cost) and then postadoption, began measurement of their in-use assets 
inconsistent with their use (measured at fair value). I again estimate value relevance 
regressions of stock price and returns, and mechanical forecasting models of operating 
cash flows and operating income for the switcher sample. I limit my sample to firm-year 
observations with at least one year of pre-IAS 41 data.  
In both my cross-sectional and switcher tests, I include no more than five years of 
pre-IAS 41 data for the following reason. I assume that the type of biological assets the 
firm held upon adoption of IAS 41, either in-use or in-exchange, are the type of 
biological assets that the firm held in the prior five years since these data are 
unobservable in the pre-IAS 41 period. If one assumes that a firm’s business model is 
stable over more than five years, this is a conservative assumption in that it excludes 





better ensure that my inferences with respect to the pre-IAS 41 data are driven by the 
value relevance of the biological assets, not other unrelated asset or business choices the 
firm might have made in a preperiod of greater length than five years.10 Further, several 
of the firms in my sample have close to 20 years of pre-IAS 41 data. By restricting the 
pre-IAS 41 data to five years, I can better ensure that one firm’s data or a limited sample 
of firms are not driving my results. 
 
4.1 Consistent and Inconsistent Measurement Samples 
I sort firm-year observations into the consistent and inconsistent measurement 
samples in the following manner. I employ IAS 41’s definition of consumable and bearer 
biological assets to represent in-exchange and in-use biological assets, respectively. To 
be classified as consistent, I group firm-year observations where in-exchange biological 
assets are measured at fair value (216 firm-year observations) or in-use biological assets 
are measured at historical cost (607 firm-year observations) (see Figure 3.1).  To be 
classified as inconsistent, I group firm-year observations where in-use biological assets 
are measured at fair value (343 firm-year observations) or in-exchange biological assets 
are measured at historical cost (182 firm-year observations) (see Figure 3.1). Recall that 
for the pre-IAS 41 historical cost data, I assume that the type of biological assets the firm 
held in the year it adopted IAS 41, either in-use or in-exchange, is the type of biological 
assets the firm held in the pre-adoption period.  
My sample is limited to firm-year observations drawn from firms for which all of 
their biological assets are measured on a consistent or inconsistent basis. Mixed 
measurement firms are those which measure some biological assets on a consistent basis 
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and some on an inconsistent basis. I exclude firm-year observations from such mixed 
measurement firms (270 firm-year observations). I do so to ensure clear predictions 
regarding my measurement samples. This provides a sample of 823 firm-year 
observations for the consistent measurement sample and 525 firm-year observations for 
the inconsistent measurement sample. 
 
4.2 Interpretation of the Results 
For the cross-sectional tests, I estimate all models on the pooled sample and then 
separately by measurement basis. I evaluate results in the following manner. If value 
relevant asset measurement is linked to asset use, then I expect the variables for the 
consistent sample, in the stock price and return models and the mechanical forecasting 
models of operating cash flows and operating income, to be incrementally more 
significant than the variables for the inconsistent sample. Specifically, the evidence 
would suggest that firm inputs are relatively more predictive of firm performance when 
measurement is consistent with asset use (the consistent sample), relative to when it is not 
(the inconsistent sample).  
In the switcher sample design, I expect that postadoption of IAS 41, the value 
relevance of firms’ book value and earnings information will significantly improve for 
the sample of firms that held in-exchange biological assets and began measuring them at 
fair value upon adoption of the standard. On the other hand, I expect that postadoption of 
IAS 41, the value relevance of firms’ book value and earnings information will 
significantly decline for the sample of firms that held in-use biological assets and upon 





support of my hypothesis, that measurement linked to asset use provides investors with 
relatively more value relevant information than asset measurement that is not linked to 
asset use. 
 
4.3 Price and Return Tests 
 I follow prior value relevance research and examine value relevance regressions 
of price and returns. In a vein similar to Easton et al. (1993), Barth and Clinch (1998), 
and Aboody et al. (1999), I estimate the following cross-sectional model on the pooled 
sample and then by measurement basis:  
 
,    	 
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  ,  	   4.1 
 
In model (4.1), , is the share price for firm i one month following the annual 
report filing or, alternatively, four months following the end of the firm’s fiscal year-
end;  is a dummy variable that takes the value of one for firm-year observations 
classified in the consistent measurement sample; ,  is the firm’s book value per 
share at the end of the fiscal year; and ,  is earnings per share at fiscal year-end 
excluding any unrealized gains or losses (URGL) related to the fair value of the 
biological assets recognized in income. I include the URGL related to the fair value of the 
biological assets in the BVPS term because this is the variable I interact with CON in 
testing my hypothesis. I include the interaction term to examine whether firms’ book 
value is incrementally more value relevant when biological assets are measured 





are not, i.e. the inconsistent sample. 
 I then estimate a variation of model (4.1) for the switcher sample: 
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In model (4.2), POST is an indicator variable that takes a value of one if the firm-
year observation falls in the post-IAS 41 period and CHG_CON is an indicator variable 
that takes a value of one if the firm holds in-exchange biological assets. All other 
variables are defined above. In model (4.2), the variables of interest are:   which 
captures the value relevance of BVPS pre-IAS 41 for firms that held in-exchange 
biological assets and measured them at cost; ! which captures the value relevance of 
BVPS post-IAS 41 for firms that held in-use biological assets and measured them at fair 
value; and finally, " which captures the value relevance of BVPS post-IAS 41 for firms 
that held in-exchange biological assets and measured them at fair value. If my hypothesis 
is supported, I expect "  to be significantly positive, and I expect   and !  to be 
significantly negative. These findings would suggest that firms’ BVPS significantly 
increased in value relevance once firms’ that held in-exchange biological assets began 
measuring them at fair value ("), compared to when firms measured their in-exchange 
biological assets at historical cost pre-IAS 41 ( ), and firms that held in-use biological 
assets and began measuring them at fair value postadoption of IAS 41 experienced a 





I also include the changes estimation of model (4.1), following Easton et al. 
(1993), Barth and Clinch (1998), and Aboody et al. (1999). Specifically, I estimate the 
following cross-sectional model on the pooled sample and then by measurement basis: 
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In model (4.3), $%&, is the firm i's cumulative 12-month raw return ending the 
month following the annual report filing or, alternatively, four months following the end 
of the firm’s fiscal year-end; ', is the firm’s net income for the fiscal year; and (', 
is the change in net income over the fiscal year. I include the interaction term to examine 
whether net income is incrementally more value relevant for firm returns when 
measurement is consistent with asset use. All variables are deflated by beginning period 
market value of equity.  
 Finally, I estimate a variation of model (4.3) for the switcher sample: 
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All variables are defined above. In model (4.4), the variables of interest are:   
which captures the value relevance of firms’ NI pre-IAS 41 for firms that held in-
exchange biological assets and measured them at cost; !  which captures the value 





measured them at fair value; and finally " which captures the value relevance of firms’ 
NI post-IAS 41 for firms that held in-exchange biological assets and measured them at 
fair value. If my hypothesis is supported, I expect " to be significantly positive, and I 
expect   and ! to be significantly negative. These findings would suggest that firms’ 
NI significantly increased in value relevance once firms that held in-exchange biological 
assets began measuring them at fair value ("), compared to when firms measured their 
in-exchange biological assets at historical cost pre-IAS 41 ( ), and firms that held in-use 
biological assets and began measuring them at fair value postadoption of IAS 41 
experienced a decline in the value relevance of their NI (!). 
I estimate standard errors clustered by firm for models (4.1)-(4.4) and I winsorize 
the price and return samples at the second and 98th percentiles to minimize the influence 
of outliers. In addition, I include country and year fixed effects in all estimations in order 
to control for unobservable, confounding variables that differ across firms, but are 
constant over time and across country. 
 
4.4 Mechanical Forecast Models  
 I examine whether asset measurement linked to asset use influences the ability of 
a mechanical forecasting model of firms’ future operating cash flows and operating 
income. I follow prior international accounting research to estimate forecasts of both 
operating cash flows and income (e.g. Barth et al. 2012). The operating cash flows model 
for the cross-sectional test appears below, which I estimate on the pooled sample and 
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where net operating cash flows for firm i , *+
, one period ahead of fiscal year t are a 
function of: operating cash flows for fiscal year t, *,; and ', net income for fiscal 
year t. In addition to future operating cash flows, I estimate model (4.5), including the 
sum of future operating cash flows one, two, and three periods ahead of fiscal year t, as 
the dependent variable. I include the interaction term to examine whether net income is 
incrementally more predictive of future operating cash flows when measurement is 
consistent with asset use. All variables are deflated by average total assets.  
 I estimate a variation of model (4.5) for the switcher sample: 
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All variables are defined above. In addition to future operating cash flows, I 
estimate model (4.6), including the sum of future operating cash flows one, two, and 
three periods ahead of fiscal year t, as the dependent variable. In model (4.6), the 
variables of interest are:   which captures the value relevance of firms’ NI pre-IAS 41 
for firms that held in-exchange biological assets and measured them at cost; ! which 
captures the value relevance of firms’ NI post-IAS 41 for firms that held in-use biological 
assets and measured them at fair value; and finally " which captures the value relevance 
of firms’ NI post-IAS 41 for firms that held in-exchange biological assets and measured 





and I expect   and ! to be significantly negative. These findings would suggest that 
firms’ NI significantly increased in value relevance once firms’ that held in-exchange 
biological assets began measuring them at fair value (" ), compared to when firms 
measured their in-exchange biological assets at historical cost pre-IAS 41 ( ), and firms 
that held in-use biological assets and began measuring them at fair value postadoption of 
IAS 41 experienced a decline in the value relevance of their NI (!). 
 The operating income model I estimate for the cross-sectional test appears below, 
which I estimate on the pooled sample and then by measurement basis: 
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where operating income for firm i, /_',+
, one period ahead of fiscal year t is a 
function of: the current period’s operating income, /_', ; and lagged operating 
income, /_',.
. I calculate operating income using the S&P Capital IQ variable 
“earnings from continuing operations,” which includes unrealized gains and losses 
related to biological assets. Again, I include the interaction term to examine whether 
operating income is incrementally more predictive of future operating income when 
measurement is consistent with asset use.  
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All variables are defined above. In model (4.8), the variables of interest are:   
which captures the value relevance of firms’ OP_INC pre-IAS 41 for firms that held in-
exchange biological assets and measured them at cost; !  which captures the value 
relevance of firms’ OP_INC post-IAS 41 for firms that held in-use biological assets and 
measured them at fair value; and finally " which captures the value relevance of firms’ 
OP_INC post-IAS 41 for firms that held in-exchange biological assets and measured 
them at fair value. If my hypothesis is supported, I expect " to be significantly positive, 
and I expect   and ! to be significantly negative. These findings would suggest that 
firms’ OP_INC significantly increased in value relevance once firms that held in-
exchange biological assets began measuring them at fair value ("), compared to when 
firms measured their in-exchange biological assets at historical cost pre-IAS 41 ( ), and 
firms that held in-use biological assets and began measuring them at fair value 
postadoption of IAS 41 experienced a decline in the value relevance of their OP_INC 
(!). 
 All variables in models (4.5)-(4.8) are deflated by average total assets and are 
winsorized at the second and 98th percentiles to minimize the influence of outliers. I 
estimate all standard errors clustered by firm. In addition, I include country and year 
fixed effects in all estimations in order to control for unobservable, confounding variables 










  IAS 41 
   





























SAMPLE SELECTION AND DESCRIPTIVE STATISTICS 
 
5.1 Sample Identification and Data Sources 
I identify firms that hold biological assets by conducting a word search in the 
Morningstar Document Research Global Report’s subscription and in the S&P Capital 
IQ databases. I search on the phrase “biological assets.” I supplement this search with a 
report issued by the Institute of Charted Accountants of Scotland that lists Australian, 
U.K., and French firms that hold biological assets (see Elad and Herbohn 2011, Appendix 
1). I restrict the Morningstar and the S&P Capital IQ searches to annual report filings. I 
then eliminate firms with biological assets that comprise less than 5% of the firm’s total 
assets (433 firm-year observations). I eliminate firm-year observations where book equity 
is negative (11 firm-year observations). I further eliminate firms that have less than $1 
million U.S. Dollars (USD) in total assets, or fewer than five years of financial statement 
data available on the S&P Capital IQ database to eliminate outliers from my estimations 
that may have undue influence on the results (55 firm-year observations). 
I hand-collect the IAS 41 data. Specifically, for each fiscal year in my sample, I 
hand-collect the following amounts: the balance sheet value of the biological assets; any 





income statement or in the footnote; the classification of the biological assets as 
consumable or bearer; and whether the firm measures the biological assets at fair value or 
historical cost. I collect all financial statement data from S&P Capital IQ and I collect all 
price and return data from Datastream.  
For firms that are cross-listed on different exchanges, I calculate the price and 
return variables using aggregated market data.11 Specifically, I sum the market value and 
the shares outstanding across all cross-listed market exchanges. I then calculate an 
aggregate firm price by dividing the aggregated market cap by the aggregated shares 
amount. I calculate an aggregate firm return by value-weighting the monthly returns from 
all the cross-listed market exchanges by market cap.  
I pull all financial statement, price, and return data converted to USD from the 
respective databases. The hand-collected data, on the other hand, are reported in the filing 
currency. I convert the hand-collected amounts to USD using the ratio of S&P Capital 
IQ’s total assets reported in the firm’s filing currency to S&P Capital IQ’s total assets 
reported for the firm in USD to calculate a historical conversion rate. This way I convert 
the hand-collected amounts using the same historical conversion rate S&P Capital IQ 
used for the other firm financial statement data. I convert all data to USD for descriptive 
ease. 
 
5.2 Descriptive Statistics 
Figure 5.1 provides the sample composition for the switcher sample by pre- and 
postadoption periods, and value realization, either in-use or in-exchange. Recall that 
firms are included in the switcher sample if they have at least one year and no more than 
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five years of preperiod data. This provides a sample of 154 firms. The majority of the 
sample holds in-use assets (66%). Further, preperiod data account for 42% of the sample 
while postadoption data account for 58% of the sample. 
Table 5.1 provides descriptive statistics for the composition of the cross-sectional 
sample by country. The sample is comprised of 182 firms from 33 different countries (see 
Table 5.1). Approximately 42% of the firms in the sample are located in Australia, 
Malaysia, or Singapore. Table 5.2 provides descriptive statistics for the composition of 
the cross-sectional sample by fiscal year and measurement basis. The cross-sectional 
sample spans 1996-2011 (see Table 5.2). The historical cost observations comprise the 
early years of the sample while the fair value sample is concentrated in the latter half of 
the sample period, coinciding with the increased country-level adoption of IFRS. The fair 
value firm-year observations from 1999-2001 are Australian firms that reported the fair 
value of their regenerating and self-generating assets under the Australian standard 
AASB 1037 that predated IAS 41. I include these observations in the sample because 
they provide variation in value realization and asset measurement.12 
Table 5.3 provides descriptive statistics for the cross-sectional sample that 
measures their biological assets at fair value. The descriptive statistics are presented by 
consistent and inconsistent measurement sample. All data are reported in USD and 
winsorized at the second and 98th percentiles to reduce the influence of outliers on results. 
Results from t-statistic tests of differences in means and medians between the consistent 
and inconsistent samples are reported in the consistent sample tables.  
Table 5.3 shows that consistent sample of firms that measure their biological 
assets at fair value is significantly less profitable, on average and at the median, in terms 
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of operating cash flows ($0.03 versus $0.05), net income ($0.02 versus $0.05), operating 
income ($0.02 versus $0.05), and future operating income ($0.03 versus $0.06). This 
finding is possibly related to the difference in firms’ business models. Specifically, firms 
that hold in-exchange assets (the consistent sample) are less profitable than firms that 
hold in-use assets (the inconsistent sample) because firms with in-use assets take on more 
risk and therefore require a higher return: in-use assets (bearer biological assets) take 
longer to produce future revenue than in-exchange assets (consumable biological assets). 
There is no significant difference at the mean between the consistent and inconsistent 
samples for the price and return variables. Further, both the consistent and inconsistent 
samples hold on average 25% of biological assets comprising total assets. In addition, 
both samples have average price per share of approximately $5.00. 
Table 5.4 provides descriptive statistics for the cross-sectional sample that 
measures their biological assets at historical cost. The descriptive statistics are presented 
by consistent and inconsistent measurement sample. All data are reported in USD and 
winsorized at the second and 98th percentiles to reduce the influence of outliers on results. 
Results from t-statistic tests of differences in means and medians between the consistent 
and inconsistent samples are reported in the consistent sample tables.  
Table 5.4 shows that consistent sample of firms that measure their in-use 
biological assets at historical cost is significantly larger in terms of observations for the 
price and return estimations: 440 observations for the consistent sample versus 85 
observations for the inconsistent sample. The sample is comprised of few firms that 
measure their in-exchange biological assets at historical cost. Nevertheless, the consistent 





($0.08 versus $0.01), and returns (0.26 versus 0.17). This finding is again consistent with 
differences in firms’ business models. Specifically, firms that hold in-use assets (the 
consistent sample) are more profitable and have a higher return than firms that hold in-
exchange assets (the inconsistent because firms with in-use assets take on more risk and 
require a higher return: in-use assets (bearer biological assets) take longer to produce 
future revenue than in-exchange assets (consumable biological assets). There is no 
significant difference between the two samples with respect to mechanical forecasting 
model variables.  
Table 5.5 provides descriptive statistics for the switcher sample. The descriptive 
statistics are presented by consistent and inconsistent measurement sample. All data are 
reported in USD and winsorized at the second and 98th percentiles to reduce the influence 
of outliers on results. Results from t-statistic tests of differences in means and medians 
between the consistent and inconsistent samples are reported in the consistent sample 
tables.  
Table 5.5 shows that consistent sample of switcher firms is significantly less 
profitable than the inconsistent sample of switcher firms. The consistent switcher sample 
is less profitable, on average, than the inconsistent switcher sample in terms of operating 
cash flows ($0.01 versus $0.06), net income ($0.01 versus $0.04), future operating cash 
flows ($0.02 versus $0.06), operating income (-$0.01 versus $0.04), and future operating 
income (-$0.01 versus $0.05). This finding continues to support my assertion that the 
difference in profitability is related to the different business models required for in-use 
versus in-exchange biological assets. Specifically, firms that hold in-exchange assets (the 





sample) because firms with in-use assets take on more risk and therefore require a higher 
return: in-use assets (bearer biological assets) take longer to produce future revenue than 










PRE-IAS 41 POST-IAS 41 
HC FV 
IN-USE 
222 292 514 
28% 37% 66% 
IN-EXCH 
106 162 268 
14% 21% 34% 
TOTAL 155 368 782 
42% 58% 100% 
 
Figure 5.1 







Cross-Sectional Sample Composition by Country 
Country Firms % of Total 
Australia 23 12.60% 
Brazil 9 4.90% 
Canada 7 3.80% 
Channel Islands 2 1.10% 
Chile 4 2.20% 
China 3 1.60% 
Denmark 1 0.50% 
Finland 3 1.60% 
Greece 2 1.10% 
Hong Kong 9 4.90% 
Indonesia 1 0.50% 
Jamaica 1 0.50% 
Latvia 3 1.60% 
Lithuania 1 0.50% 
Luxembourg 2 1.10% 
Malaysia 41 22.40% 
Mauritius 1 0.50% 
Mexico 1 0.50% 
Netherlands 1 0.50% 
New Zealand 7 3.80% 
Norway 8 4.40% 
Peru 2 1.10% 
Philippines 4 2.20% 
Portugal 2 1.10% 
Singapore 12 6.60% 
South Africa 6 3.30% 
Spain 1 0.50% 
Sri Lanka 9 4.90% 
Sweden 3 1.60% 
Switzerland 1 0.50% 
Turkey 1 0.50% 
Ukraine 3 1.60% 
United Kingdom 7 3.80% 
Zambia 1 0.50% 








Cross-Sectional Sample Composition by Fiscal Year 








1996 2 0 2 
1997 5 0 5 
1998 17 0 17 
1999 29 1 30 
2000 36 2 38 
2001 44 6 50 
2002 56 8 64 
2003 72 17 89 
2004 74 27 101 
2005 75 34 109 
2006 77 46 123 
2007 76 56 132 
2008 75 80 155 
2009 60 91 151 
2010 51 94 145 
2011 40 97 137 








Descriptive Statistics for the Fair Value Cross-Sectional Sample 
 
Consistent Sample – In-Exchange Assets at Fair Value 
Variable Obs Mean Median St. Dev. 
FV BIO % 141 0.25 0.23* 0.17 
MVE 141 1056.01 199.50 2202.66 
PRICE 141 5.97 1.36 9.19 
EPS 141 0.21* 0.05 0.85 
BVPS  141 4.50 1.55 6.54 
RETURN 141 0.17 0.00 0.77 
CF 216 0.03*** 0.04 0.11 
NI 216 0.02*** 0.04*** 0.11 
FUT CF 216 0.05 0.05 0.12 
LAG OP_INC 216 0.01*** 0.03*** 0.11 
OP_INC 216 0.02*** 0.04*** 0.11 
FUT OP_INC 216 0.03** 0.04*** 0.14 




Inconsistent Sample – In-Use Assets at Fair Value 
Variable Obs Mean Median St. Dev. 
FV BIO % 266 0.25 0.18 0.18 
MVE 266 1204.16 166.74 2958.65 
PRICE 266 4.96 1.08 7.90 
EPS 266 0.33 0.10 0.70 
BVPS  266 4.61 1.27 8.26 
RETURN 266 0.18 0.08 0.65 
CF 343 0.05 0.06 0.08 
NI 343 0.05 0.05 0.10 
FUT CF 343 0.06 0.06 0.09 
LAG OP_INC 343 0.04 0.05 0.10 
OP_INC 343 0.05 0.06 0.11 
FUT OP_INC 343 0.06 0.06 0.12 







Descriptive Statistics for the Historical Cost Cross-Sectional Sample 
 
 
Consistent Sample – In-Use Assets at Historical Cost 
Variable Obs Mean Median St. Dev. 
BV BIO % 237 0.21** 0.16** 0.17 
MVE 440 533.43* 66.82 1781.98 
PRICE 440 1.54 0.39 3.71 
EPS 440 0.08** 0.03*** 0.23 
BVPS  440 1.09** 0.41* 2.32 
RETURN 440 0.26** 0.16*** 0.69 
CF 607 0.06 0.06 0.08 
NI 607 0.04 0.04 0.09 
FUT CF 607 0.07 0.07 0.10 
LAG OP_INC 607 0.03 0.04 0.08 
OP_INC 607 0.04 0.04 0.08 
FUT OP_INC 607 0.05* 0.05* 0.10 




Inconsistent Sample – In-Exchange Assets at Historical Cost 
Variable Obs Mean Median St. Dev. 
BV BIO % 54 0.27 0.19 0.24 
MVE 85 190.53 63.52 278.92 
PRICE 85 1.41 0.34 3.20 
EPS 85 0.01 0.01 0.33 
BVPS  85 1.83 0.53 4.18 
RETURN 85 0.17 0.01 0.78 
CF 182 0.05 0.05 0.10 
NI 182 0.03 0.04 0.10 
FUT CF 182 0.06 0.06 0.11 
LAG OP_INC 182 0.02 0.03 0.10 
OP_INC 182 0.03 0.04 0.10 
FUT OP_INC 182 0.03 0.04 0.11 






Descriptive Statistics for the Switcher Sample 
 
Consistent Sample – In-Exchange Assets at Fair Value 
Variable Obs Mean Median St. Dev. 
FV BIO % 164 0.15 0.10 0.19 
MVE 164 887.48 128.54 2075.27 
PRICE 164 3.86 0.82 7.11 
EPS 164 0.11*** 0.03** 0.65 
BVPS  164 3.04 0.72** 5.38 
RETURN 164 0.12** -0.01 0.67 
CF 268 0.03*** 0.05 0.11 
NI 268 0.02** 0.04** 0.11 
FUT CF 268 0.04** 0.05 0.12 
LAG OP_INC 268 0.01*** 0.03* 0.11 
OP_INC 268 0.02*** 0.04** 0.12 
FUT OP_INC 268 0.03*** 0.04*** 0.14 




Inconsistent Sample – In-Use Assets at Fair Value 
Variable Obs Mean Median St. Dev. 
FV BIO % 359 0.15 0.10 0.17 
MVE 359 1013.18 120.60 2585.13 
PRICE 359 4.56 0.90 7.47 
EPS 359 0.29 0.07 0.64 
BVPS  359 4.08 1.13 7.50 
RETURN 359 0.27 0.15 0.79 
CF 514 0.05 0.06 0.08 
NI 514 0.04 0.04 0.09 
FUT CF 514 0.06 0.06 0.10 
LAG OP_INC 514 0.03 0.04 0.08 
OP_INC 514 0.04 0.05 0.09 
FUT OP_INC 514 0.05 0.05 0.11 












6.1 Cross-Sectional Results 
6.1.1 Price and Return Results  
Table 6.1 presents the results from the cross-sectional price estimation. Column 
(1) presents the results for the full sample, while columns (2) and (3) present the results 
for the sample of firms that measure their biological assets at fair value, and the sample 
of firms that measure their biological assets at historical cost, respectively. All 
estimations include country and year fixed effects in order to control for unobservable, 
confounding variables that differ across firms, but are constant over time and across 
country.  
Consistent with prior value relevance research, both book value and earnings per 
share are significantly, and positively, associated with price in all estimations. Further, 
the book value per share for the sample of firms that measure their biological assets 
consistent with their use is significantly more value relevant than the book value of firms 
that measure their biological assets inconsistent with their use. This result holds for both 
the fair value and historical cost samples. Specifically, when firms measure their in-





book value is significantly more value relevant than firms that measure their in-use assets 
at fair value and their in-exchange assets at historical cost (see Table 6.1, columns (1) - 
(3)). The price results strongly support my first hypothesis, that when firms measure their 
biological assets consistent with their use, they provide investors with more value 
relevant information than firms that do not measure their biological assets consistent with 
their use. 
Table 6.2 presents the results from the cross-sectional return estimation. Column 
(1) presents the results for the full sample, while columns (2) and (3) present the results 
for the sample of firms that measure their biological assets at fair value, and the sample 
of firms that measure their biological assets at historical cost, respectively. Again, all 
estimations include country and year fixed effects in order to control for unobservable, 
confounding variables that differ across firms, but are constant over time and across 
country. 
The return results for the full sample (see Table 6.2, column (1)) suggest that 
when firms measure their biological assets consistent with their use, they provide 
investors with significantly more value relevant net income than firms that do not 
measure their biological assets consistent with their use. Again, this result holds for both 
the fair value and historical cost samples (see Table 6.2, columns (2) and (3)). Overall, 
the return results in Table 6.2 confirm the findings in Table 6.1, that when firms measure 
their biological assets consistent with their use, they provide investors with significantly 
more value relevant earnings information in return estimations than firms that do not 
measure their biological assets consistent with their use.  





when asset measurement is linked to asset use, firm inputs to price and return estimations 
are significantly more value relevant than when measurement is not linked to asset use. 
 
6.1.2 Operating Cash Flows and Operating Income Results 
Table 6.3 presents the results from the mechanical forecasting model of future 
operating cash flows. Column (1) presents the results for the full sample, while columns 
(2) and (3) present the results for the sample of firms that measure their biological assets 
at fair value, and the sample of firms that measure their biological assets at historical 
cost, respectively. All estimations include country and year fixed effects in order to 
control for unobservable, confounding variables that differ across firms, but are constant 
over time and across country.  
The results for the full sample in Table 6.3 (see column (1)) suggest that when 
measurement is linked to assets’ use, firms’ net income is significantly more predictive of 
the next year’s operating cash flows. However, the results for the full sample appear to be 
driven by the fair value sample and not the historical cost sample (see Table 6.3, columns 
(2) and (3)). Specifically, the results suggest that net income is significantly more 
predictive of future operating cash flows when in-exchange assets are measured at fair 
value relative to when in-use assets are measured at fair value (see Table 6.3, column 
(2)). However, it does not appear that net income is significantly more predictive of 
future operating cash flows when in-use assets are measured at historical cost relative to 
when in-exchange assets are measure at historical cost (see Table 6.3, column (3)). 
Table 6.4 presents the results from the mechanical forecasting model of the sum 





Column (1) presents the results for the full sample, while columns (2) and (3) present the 
results for the sample of firms that measure their biological assets at fair value, and the 
sample of firms that measure their biological assets at historical cost, respectively. All 
estimations include country and year fixed effects in order to control for unobservable, 
confounding variables that differ across firms, but are constant over time and across 
country.  
The results in Table 6.4, column (1) demonstrate no difference in the 
predictability of net income for the sum of future operating cash flows between the 
consistent and inconsistent samples. Thus, net income is not significantly more predictive 
for the consistent sample beyond the first year of future operating cash flows. This result 
holds for both the fair value and historical cost samples (see Table 6.4, columns (2) and 
(3)). Overall, the results in Table 6.4 suggest that the incremental predictive ability of the 
consistent sample’s net income for future operating cash flows is restricted to the first 
year of future operating cash flows, not beyond the first year. 
Finally, Table 6.5 presents the results from the mechanical forecasting model of 
future operating income. Column (1) presents the results for the full sample, while 
columns (2) and (3) present the results for the sample of firms that measure their 
biological assets at fair value, and the sample of firms that measure their biological assets 
at historical cost, respectively. All estimations include country and year fixed effects in 
order to control for unobservable, confounding variables that differ across firms, but are 
constant over time and across country. 
The results in Table 6.5 suggest that when firms measure their biological assets 





future operating income, relative to firms that do not measure their biological assets 
consistent with their use. Again, the results hold for both the fair value and historical cost 
samples. Specifically, when firms measure their in-exchange biological assets at fair 
value and their in-use assets at historical cost, their operating income is significantly 
more predictive of their future operating income than firms that measure their in-use 
assets at fair value and their in-exchange assets at historical cost (see Table 6.5, columns 
(2) and (3)).  
Collectively, the results from the mechanical forecasting models of future 
operating cash flows and operating income provide strong support for my hypothesis. 
Specifically, the results suggest that when measurement is consistent with the biological 
assets’ use, net income and operating income are significantly more predictive of future 
firm performance.  
 
6.2 Switcher Sample Results 
6.2.1 Price and Return Results 
 Table 6.6 presents the results from the switcher sample price estimation. I include 
country and year fixed effects in the estimation in order to control for unobservable, 
confounding variables that differ across firms, but are constant over time and across 
country. 
The results support my main hypothesis. Specifically, the results in Table 6.6 
suggest that book value per share became significantly more value relevant for the 
sample of firms that held in-exchange biological assets and began measuring them at fair 





results in Table 6.6 suggest that book value per share became significantly less value 
relevant for the sample of firms that held in-use biological assets and began measuring 
them at fair value upon adoption of IAS 41 (POST*BVPS). Moreover, the results in 
Table 6.6 also suggest that book value per share was significantly less value relevant 
when firms measured their in-exchange biological assets at historical cost, pre-adoption 
of IAS 41 (CHG_CON*BVPS). The price results provide strong support for my main 
hypothesis that measurement linked to asset use provides investors with significantly 
more value relevant information. 
Table 6.7 presents the results from the switcher sample return estimation. I 
include country and year fixed effects in the estimation in order to control for 
unobservable, confounding variables that differ across firms, but are constant over time 
and across country. Overall, I find no statistically significant results, although the signs of 
the coefficients of interest support my hypothesis. Specifically, the sign on the 
CHG_CON*POST*NI coefficient in Table 6.7 is positive, while the signs on both 
CHG_CON*NI and POST*NI are negative,. The coefficients, however, are not 
statistically different from zero. 
Collectively, the price results for the switcher sample support my main 
hypothesis, while I find no evidence in the return switcher estimation. 
   
6.2.2 Operating Cash Flows and Operating Income Results 
Table 6.8 presents the results from the switcher sample mechanical forecasting 
model of future operating cash flows, while Table 6.9 presents the results from the 





one, two, and three years following the current fiscal year. I include country and year 
fixed effects in the estimations in order to control for unobservable, confounding 
variables that differ across firms, but are constant over time and across country. 
Again, I find no significant results. In Table 6.8, the sign on the 
CHG_CON*POST*NI coefficient is positive while the sign on the CHG_CON*NI 
coefficient is negative, consistent with my predictions, but the sign on the POST*NI 
coefficient is positive, opposite my prediction. None of the coefficients are statistically 
different from zero. Further, none of the coefficients of interest in Table 6.9 have the 
predicted signs, even though the coefficients are, again, not statistically different from 
zero. 
Finally, Table 6.10 presents the results from the switcher sample mechanical 
forecasting model of future operating income. I include country and year fixed effects in 
the estimation in order to control for unobservable, confounding variables that differ 
across firms, but are constant over time and across country. 
Again, I find no significant results. In Table 6.10, the sign on the 
CHG_CON*POST*OP_INC coefficient is positive, but the signs on the 
CHG_CON*OP_INC coefficient and the POST* OP_INC coefficient are positive, 
opposite my predictions. None of the coefficients are statistically different from zero, 
however.  
Overall, I find no support for my hypothesis in the switcher sample tests of future 







Cross-Sectional Price Results 
 
    (1)   (2)   (3) 
FULL FV HC 
VARIABLES Expectations PRICE PRICE PRICE 
              
CON -0.394 -0.775** -0.358* 
(-1.466) (-2.093) (-1.923) 
BVPS + 0.832*** 0.749*** 0.540* 
(9.070) (7.748) (1.891) 
EPS + 0.866*** 0.700*** 2.973*** 
(3.631) (2.881) (3.434) 
CON*BVPS + 0.365***   0.312**   0.865*** 
    (3.558)   (1.765)   (3.005) 
INTERCEPT 0.141 1.328** -0.029 
(0.334) (2.487) (-0.108) 
Observations 932 407 525 
R-squared   0.863   0.890   0.822 
Country FE Y Y Y 








Cross-Sectional Return Results 
 
    (1)   (2)   (3) 
FULL FV HC 
VARIABLES Expectations RET RET RET 
              
CON 0.105** -0.011 0.085 
(2.071) (-0.124) (1.063) 
NI + -0.012 0.143 -0.673** 
(-0.059) (0.657) (-2.400) 
CHG_NI + 0.115 0.114 0.329 
(1.380) (1.004) (1.231) 
CON*NI + 0.582**   0.558**   1.104*** 
    (2.474)   (2.067)   (3.544) 
INTERCEPT -0.262** 0.304*** -0.036 
(-2.593) (4.966) (-0.408) 
Observations 932 407 525 
R-squared   0.235   0.288   0.282 
Country FE Y Y Y 











Cross-Sectional Operating Cash Flows Results 
 
    (1)   (2)   (3) 
FULL FV HC 
VARIABLES Expectations FUT CF FUT CF FUT CF 
              
CON -0.001 0.003 0.002 
(-0.166) (0.270) (0.186) 
CF + 0.359*** 0.503*** 0.232*** 
(6.130) (6.015) (3.001) 
NI + 0.184*** 0.139*** 0.252** 
(3.559) (2.674) (2.176) 
CON*NI + 0.143***   0.117*   0.110 
    (2.613)   (1.428)   (0.980) 
INTERCEPT 0.142*** 0.096*** 0.121*** 
(4.795) (7.029) (5.056) 
Observations 1,348 559 789 
R-squared   0.366   0.500   0.305 
Country FE Y Y Y 











Cross-Sectional Sum of Future Operating Cash Flows Results 
 
    (1)   (2)   (3) 








              
CON -0.012 -0.001 -0.002 
(-0.657) (-0.019) (-0.080) 
CF + 1.111*** 1.259*** 0.964*** 
(7.269) (4.592) (5.316) 
NI + 0.559*** 0.573** 0.465 
(3.264) (2.510) (1.465) 
CON*NI + 0.153   0.074   0.248 
    (0.764)   (0.226)   (0.703) 
INTERCEPT 0.203*** 0.151*** 0.190*** 
(4.454) (2.835) (3.663) 
Observations 1,182 453 729 
R-squared   0.453   0.583   0.384 
Country FE Y Y Y 






Cross-Sectional Operating Income Results 
 
    (1)   (2)   (3) 
FULL FV HC 
VARIABLES Expectations FUT OP FUT OP FUT OP 
              
CON -0.008 -0.016 0.017 
(-1.344) (-1.107) (1.371) 
OP_INC + 0.541*** 0.556*** 0.470*** 
(8.652) (6.346) (4.083) 
LAG_OP_INC + 0.149*** 0.107 0.172** 
(2.605) (1.454) (2.278) 
CON*OP_INC + 0.141**   0.179*   0.159* 
    (1.929)   (1.344)   (1.355) 
INTERCEPT -0.026 0.082*** -0.062 
(-0.343) (5.382) (-0.645) 
Observations 1,348 559 789 
R-squared   0.496   0.527   0.510 
Country FE Y Y Y 









Switcher Sample Price Results 
 
 
    (1) 
VARIABLES Expectations PRICE 





BVPS + 1.275*** 
(8.246) 
EPS + 1.190*** 
(3.500) 
CHG_CON *BVPS - -0.298* 
(-1.621) 
POST*BVPS - -0.463*** 
  (-3.200) 
CHG_CON *POST*BVPS + 0.515*** 




R-squared   0.884 
Country FE Y 







Switcher Sample Return Results 
 
 
    (1) 
VARIABLES Expectations RET 





NI + 0.530 
(1.178) 
CHG_NI + 0.157 
(1.275) 
CHG_CON*NI - -0.226 
(-0.383) 
POST*NI - -0.144 
  (-0.276) 
CHG_CON *POST*NI + 0.443 




R-squared   0.249 
Country FE Y 






Switcher Sample Operating Cash Flows Results 
 
 
    (1) 
VARIABLES Expectations FUT CFO 





CFO + 0.372*** 
(4.654) 
NI + 0.211** 
(2.172) 
CHG_CON*NI - -0.038 
(-0.230) 
POST*NI - 0.079 
  (0.768) 
CHG_CON*POST*NI + 0.080 




R-squared   0.413 
Country FE Y 








Switcher Sample Sum of Future Operating Cash Flows Results 
 
 









CFO + 1.221*** 
(6.285) 
NI + 0.481* 
(1.754) 
CHG_CON *NI - 0.104 
(0.248) 
POST*NI - 0.424 
  (1.153) 
CHG_CON*POST*NI + -0.428 




R-squared   0.504 
Country FE Y 








Switcher Sample Operating Income Results 
 
 
    (1) 
VARIABLES Expectations FUT OP 





OP_INC + 0.474*** 
(4.292) 
LAG_OP_INC + 0.140* 
(1.799) 
CHG_CON*OP_INC - 0.002 
(0.014) 
POST*OP_INC - 0.148 
  (1.114) 
CHG_CON *POST*OP_INC + 0.051 




R-squared   0.492 
Country FE Y 










7.1 Reliability Test 
 Fair value advocates argue that as long as fair value can be estimated reliably 
enough, with a Level 1 estimate as defined by the fair value hierarchy established under 
SFAS 157, then it will provide investors with value relevant information (e.g. Barth and 
Landsman 1995; Dietrich et al. 2000; Barth et al. 2001; Landsman 2007). Instead, I argue 
that when measurement is linked to asset use, it will provide investors with value relevant 
information. Specifically, I argue that historical cost applied to in-use (in-exchange) 
assets and fair value applied to in-exchange (in-use) assets provides investors with more 
(less) value relevant information. 
 To ensure my results are not driven by systematic differences in the reliability of 
fair value measurements between in-exchange and in-use assets, however, I investigate 
the role of reliability in my fair value findings. For example, it is possible that I find fair 
value as less relevant for in-use assets than in-exchange biological assets because the in-






Table 7.1 provides descriptive statistics for the reliability of the fair value 
estimates employed for in-exchange and in-use assets: Level 1, Level 2, and Level 3. I 
include observations for which the reliability of the fair value estimate was disclosed in 
the IAS 41 footnote. This provides a sample of 533 firm-year observations, of which 209 
observations are in-exchange assets and 324 observations are in-use assets. Table 7.1 
shows that, indeed, the majority of in-use assets, 81%, are measured with a Level 3 
estimate of fair value, while only 10% are measured with a Level 2 fair value estimate, 
and 8% are measured with a Level 1 estimate. On the other hand, Table 7.1 shows that 
44% of in-exchange assets are measured using a Level 1 estimate of fair value, while 
16% are measured with a Level 2 estimate of fair value, and 41% are measured with a 
Level 3 estimate of fair value. Table 7.1 highlights the fact that although the majority of 
in-use assets are measured using a Level 3 estimate, 44% of the in-exchange biological 
assets are also measured using a Level 3 estimate.  
Because of the variation in reliability across the two samples (see Table 7.1), I 
address the concern that reliability may be influencing my results in two ways. First, I re-
estimate the cross-sectional regressions and include a dummy variable that takes a value 
of one if the firm employs a Level 2 or Level 3 input to estimate the fair value of its 
biological assets, and zero otherwise. I intend the dummy variable to capture the effect of 
firms’ use of less reliable fair value estimates. My results are unchanged after controlling 
for cross-sectional variation via the inclusion of the indicator variable. 
The second way I address reliability is to re-estimate the cross-sectional tests on 
the fair value sample, by reliability level: Level 1, Level 2, and Level 3. This is a 





the three subsamples. Consequently, I find little statistical significance in the main 
coefficients or the interaction terms for the consistent sample. This is likely a power issue 
since the sample size is substantially reduced when I estimate each regression by level of 
reliability. I plan on addressing this issue in future work when I hand-collect the 
remaining fiscal year disclosures, discussed further in the next chapter. 
 
7.2 Robustness Tests 
I conduct several robustness tests to assess the stability of my results. First, I re-
estimate all regressions employing a robust regression estimation technique. Robust 
regression is an alternative to least squares regression when there is a possibility that 
outliers or influential observations may be driving the results. To ensure that my results 
are not driven by outliers, I re-estimate all regressions employing the robust estimation 
technique. My results are unchanged.  
Next, I explore the effect of IFRS enforcement on my results. It is possible that 
certain countries are better able to enforce IAS 41 than others because they have the 
expertise to do so. For example, certain countries may have auditors with better access to 
valuation resources who in turn provide more reliable estimates of fair value, or better 
enforce the standard, than auditors in other countries. I control for country fixed effects in 
my regression analysis, which should address this concern to some extent. Nevertheless, 
as an alternative to this control, I include an index of country-level audit enforcement 
developed in Brown et al. (2014). Brown et al. (2014) develop an audit enforcement 
index where countries receive higher scores if auditors have greater incentives to provide 





standards. Using the Brown et al. (2014) index, which is available for 24 of the countries 
in my sample, I re-estimate all my regressions by including fixed effects for the 
enforcement index, instead of country fixed effects, in order to examine whether 
differences in audit enforcement are driving my results. The results remain unchanged.  
In my primary price regression, I interact the consistent variable with BVPS but 
not EPS because I am interested in the difference between the value relevance of book 
value for the consistent and inconsistent samples. I examine the value relevance of firm 
income in the return regression and in the mechanical forecasting models. To examine the 
sensitivity of my results to this research design choice, I include an interaction of the 
consistent variable with EPS in my price regressions, in addition to the interaction with 
BVPS. I find that for the fair value sample, BVPS is significantly more value relevant, 
while EPS is significantly less value relevant for the consistent sample. This finding is 
consistent with investors placing more weight on the firm’s balance sheet than the firm’s 
earnings when a fair value model is employed (see Nissim and Penman 2008). Consistent 
with this argument, I find that both BVPS and EPS are significantly more value relevant 
for the consistent sample that measures their biological assets at historical cost. As 
Nissim and Penman (2008) argue, investors rely more heavily on earnings when a 
historical cost model is employed relative to a fair value model.  
For the cross-sectional tests, I re-estimate all fair value models and restrict the 
sample to fiscal years in 2005 and later to explore the effects of early IFRS adopters on 






In addition, I estimate the cross-sectional price models by examining the value 
relevance of the biological assets, separated out from BVPS. I find that the fair value of 
the biological assets for the consistent sample is not incrementally more value relevant 
relative to the inconsistent sample, which suggests that investors do not price the fair 
value of in-exchange and in-use assets differently. On the other hand, I find that the book 
value of the biological assets for the consistent sample is significantly more value 
relevant relative to the inconsistent sample. This result suggests that investors apply 
different multiples to in-use and in-exchange biological assets when they are measured at 
historical cost. Specifically, investors apply a higher multiple to in-use biological assets 
when they are measured at historical cost relative to in-exchange biological assets, 
consistent with in-use assets being used in combination with other firm assets to create 
value for the firm. Therefore, investors apply a higher multiple to in-use assets in order to 
capture the value the in-use assets create, relative to in-exchange assets. 
For the switcher sample tests, I re-estimate all models utilizing different samples. 
First, I estimate the switcher sample models employing firm-year observations the year 
prior to IAS 41 adoption, and the year of IAS 41 adoption. I also estimate the switcher 
sample models employing firm-year observations the year prior to IAS 41 adoption, and 
the year following IAS 41 adoption, excluding the adopting year. Finally, I estimate the 











Fair Value Firm-Year Observations by Reliability Level and Value Realization 
 
 
RELIABILITY IN-EXCHANGE IN-USE 
LEVEL 1 91 26 
44% 8% 
LEVEL 2 33 34 
16% 10% 
LEVEL 3 85 264 
  41% 81% 















 This study provides empirical evidence in support of early accounting theory, 
namely that measurement linked to asset use provides investors with more value relevant 
information. This finding is novel to the extant literature. In particular, I find support for 
early accounting theory instead of the relative reliability approach adopted by fair value 
advocates. My findings and the unique setting I employ, the adoption of IAS 41, provide 
a host of other research questions.  
 First and foremost, I plan to hand-collect IAS 41 disclosures for fiscal years 2012 
and 2013. This will increase the number of observations in my sample.  
Second, I plan to investigate whether URGL are more informative for investors 
when biological assets are measured consistent with their use, relative to when they are 
not. This will provide new evidence to the extant literature: IAS 41 is one of a few 
standards that requires fair value measurement of nonfinancial assets and is a “true” fair 
value standard. Prior research examines the informativeness of URGL recognized in 
other comprehensive income, for fair value standards that require fair value measurement 
of financial assets. Instead, I will examine the informativeness of URGL recognized in 





investors with more value relevant information, than I would expect that URGL for assets 
that derive value in-exchange versus in-use would provide investors with more value 
relevant information. 
Finally, I also hand-collected firms’ placement of the URGL related to the change 
in the fair value of the biological assets. Specifically, some firms disclose the URGL on 
the face of the income statement, while others disclose the URGL under, “other revenues 
or expenses.” I plan to investigate the pricing of the URGL depending upon the 
placement on the financial statement. Specifically, this research would provide insight 
into whether disclosing the URGL on the face of the statements versus the footnotes 












 I empirically examine whether asset measurement linked to asset use provides 
investors with relatively more value relevant information than when measurement is not 
linked to asset use. I test early accounting theory, which proposes the asset measurement 
linked to asset use provides investors with value relevant information. I test this 
framework on a sample of 182 firms from 33 different countries that adopt IAS 41. IAS 
41 prescribes fair value measurement for biological assets, which are living plants and 
animals.  
In a multipronged approach, I assess the value relevance of book value and 
earnings information in regressions of stock price, stock returns, future operating cash 
flows, and future operating income for the firms that measure their biological assets 
consistent with their use, where in-exchange biological assets are measured at fair value 
and in-use biological assets are measured at historical cost (the consistent measurement 
sample) and for the firms that measure their biological assets inconsistent with their use, 
where in-exchange biological assets are measured at historical cost and in-use assets are 
measured at fair value (the inconsistent measurement sample).  





for my hypothesis, that when measurement is linked to asset use, investors are provided 
with more value relevant information. As suggested by early accounting theorists, I find 
that book value and earnings information is more value relevant when asset measurement 
is consistent with the manner in which the asset realizes value for the firm, relative to 
when it is not. Specifically, I find that book value and earnings information is more value 
relevant when in-exchange (in-use) assets are measured at fair value (historical cost) as 
compared to when in-exchange (in-use) assets are measured at historical cost (fair value).  
I supplement my cross-sectional findings by comparing the value relevance of 
firms’ book value and earnings information for firms that switched measurement from 
historical cost to fair value upon adoption of IAS 41, the “switcher” sample. The results 
provide mixed evidence. Specifically, I find strong evidence that book value per share 
became significantly more (less) value relevant for firms that held in-exchange (in-use) 
biological assets and began measuring them at fair value upon adoption of the standard. 
However, I find no other significant results in the return tests or the mechanical 
forecasting models of future operating cash flows and operating income. In future work, I 
plan to hand-collect the interim fiscal year IAS 41 disclosures in order to increase my 
sample, and consequently, the power of the switcher test.  
Overall, my findings support an asset measurement framework that links asset 
measurement to asset use, and suggest that a measurement basis that violates the link to 




































Variable Name Definition/Calculation 
EPS The variable ‘basic_eps_incl’ from the Capital IQ database in fiscal year t. 
BVPS Book value of equity per share in fiscal year t. (Total Assets –Total Liabilities)/Common Shares Outstanding. 
CF Cash flows from operations, scaled by average total assets, in fiscal year t. 
CHG NI Change in net income, excluding the URGL, from fiscal year t to fiscal year t-1, scaled by lagged market value of equity. 
FUT CF Cash flows from operations, scaled by average total assets, in fiscal year t+1. 
FUT OP 
The variable ‘earnings from continuing operations’ from the 
Capital IQ database, scaled by average total assets, in fiscal year 
t+1.  
LAG OP_INC 
The variable ‘earnings from continuing operations’ from the 
Capital IQ database, scaled by average total assets, in fiscal year 
t-1. 
NI Net income in fiscal year t, scaled by average total assets,. 
OP_INC  
The variable ‘earnings from continuing operations’ from the 
Capital IQ database, scaled by average total assets, in fiscal year 
t. 
PRICE 
Price is calculated for the month following the annual report 
filing or, alternatively, four months following the firm’s fiscal 
year end. Data are from Datastream. 
RET 
Cumulated 12-month, raw returns over the fiscal year ending the 
month following the annual report issuance or alternatively, four 
months following the firm’s fiscal year end. Data are from 
Datastream. 
SUM FUT CF The sum of operating cash flows from fiscal year t+1, t+2, and 
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